


International Journal of Advanced Biochemistry Research



ISSN Print: 2617-4693

ISSN Online: 2617-4707

NAAS Rating: 5.29

IJABR 2025; 9(5): 66-69

www.biochemjournal.com

Received: 11-04-2025

Accepted: 15-05-2025

David Harrison

Department of Metabolic
Medicine, Manchester Institute
of Clinical Sciences,
Manchester, United Kingdom

Emma Richardson

Department of Metabolic
Medicine, Manchester Institute
of Clinical Sciences,
Manchester, United Kingdom

Uric acid metabolism, purine degradation pathways, and their pathophysiological role in the development and progression of gout

David Harrison and Emma RichardsonDOI: <https://www.doi.org/10.33545/26174693.2025.v9.i5a.7529>**Abstract**

Gout is defined as a crystal deposition disease caused by the supersaturation and precipitation of monosodium urate crystals in joints and periarticular tissues. Despite being one of the oldest recognized forms of arthritis, described in medical texts spanning over 4,500 years, gout prevalence continues to rise globally. This research investigated the relationship between purine degradation pathway activity, serum uric acid concentrations, and inflammatory marker profiles across the clinical spectrum of gout in 188 participants. Five groups were examined: healthy controls ($n = 45$), asymptomatic hyperuricemia ($n = 38$), acute gout ($n = 42$), intercritical gout ($n = 35$), and chronic tophaceous gout ($n = 28$). Serum uric acid levels showed progressive elevation from controls (5.1 ± 0.9 mg/dL) through chronic tophaceous gout (10.2 ± 1.4 mg/dL), with all gout stages exceeding the supersaturation threshold of 6.8 mg/dL. Xanthine oxidase activity measured in plasma correlated positively with uric acid levels ($r = 0.68$, $p < 0.001$). C-reactive protein and interleukin-1 β concentrations were markedly elevated during acute flares, with CRP reaching 24.7 ± 11.3 mg/L compared to 1.8 ± 0.7 mg/L in controls. The research confirmed that xanthine oxidase activity serves as an independent predictor of hyperuricemia severity and demonstrated that chronic tophaceous patients maintain a persistent low-grade inflammatory state even between acute episodes. These findings support the rationale for early urate-lowering therapy targeting xanthine oxidase to prevent progression from asymptomatic hyperuricemia to symptomatic gout.

Keywords: Uric acid, purine degradation, xanthine oxidase, gout pathophysiology, monosodium urate crystals, hyperuricemia, inflammatory markers, interleukin-1 beta, C-reactive protein, urate-lowering therapy

Introduction

Gout, in its simplest definition, is what happens when the body produces too much uric acid or excretes too little of it. The resulting hyperuricemia eventually crosses a physical chemistry threshold, and urate crystals precipitate in tissues, triggering intense inflammatory responses ^[1]. What sounds simple in principle turns out to be remarkably complex in practice, involving intricate metabolic pathways, multiple organ systems, and genetic polymorphisms affecting both production and excretion.

Uric acid represents the terminal product of purine catabolism in humans. Unlike most mammals, which express uricase to further degrade uric acid to the more soluble allantoin, humans lost functional uricase through pseudogenization roughly 15 million years ago ^[2]. This evolutionary loss elevated baseline serum urate concentrations, providing antioxidant benefits but simultaneously creating vulnerability to crystal arthropathy. The purine degradation pathway proceeds through a well-characterized sequence: adenine and guanine nucleotides are catabolized through intermediary steps to hypoxanthine and xanthine, which are then oxidized to uric acid by the enzyme xanthine oxidase ^[3].

Global gout prevalence has increased substantially over recent decades, now affecting approximately 1-4% of adults in developed countries ^[4]. Contributing factors include rising obesity rates, increased consumption of purine-rich diets and fructose-sweetened beverages, aging populations, and widespread use of thiazide diuretics and low-dose aspirin. The clinical trajectory typically progresses from asymptomatic hyperuricemia through acute

Corresponding Author:**David Harrison**

Department of Metabolic
Medicine, Manchester Institute
of Clinical Sciences,
Manchester, United Kingdom

flares, intercritical periods, and potentially to chronic tophaceous disease if urate levels remain uncontrolled [5]. While the association between hyperuricemia and gout is well established, the quantitative relationships between purine catabolic enzyme activities, specific inflammatory mediators, and disease stage progression warrant further characterization. This research measured xanthine oxidase activity alongside comprehensive urate and inflammatory profiles across five distinct clinical stages, aiming to identify metabolic parameters predictive of disease severity and progression risk [6].

Material and Methods

Material

Participants were recruited from the Rheumatology Outpatient Service of Manchester Institute of Clinical Sciences between June 2022 and October 2023. The cohort included 188 individuals distributed across five clinical categories: healthy controls without hyperuricemia ($n = 45$; mean age 54.3 ± 9.7 years), asymptomatic hyperuricemia ($n = 38$; mean age 56.8 ± 10.2 years), acute gouty arthritis within 48 hours of flare onset ($n = 42$; mean age 58.4 ± 11.1 years), intercritical gout at least three months after last flare ($n = 35$; mean age 59.7 ± 10.8 years), and chronic tophaceous gout with clinically detectable tophi ($n = 28$; mean age 62.1 ± 9.4 years). Gout diagnosis followed the 2015 ACR/EULAR classification criteria requiring monosodium urate crystal identification by polarized light microscopy [7]. Exclusion criteria included chronic kidney disease stage 3b or higher, active malignancy, and use of urate-lowering medications within six months.

Methods

Fasting venous blood samples were collected between 8:00 and 9:00 AM. Serum uric acid was quantified by enzymatic colorimetric assay using the uricase-peroxidase method on a Roche Cobas c502 analyzer. Plasma xanthine oxidase activity was determined by the pterin-based fluorometric assay, measuring isoxanthopterin formation from pterin substrate [8]. C-reactive protein was measured by high-sensitivity immunoturbidimetry. Interleukin-1 β , interleukin-6, and tumor necrosis factor- α were quantified using Luminex multiplex immunoassay panels (Bio-Rad, Hercules, CA, USA) [9]. 24-hour urinary uric acid excretion was measured to classify patients as overproducers (>800 mg/day) or underexcretors. Statistical analysis employed one-way ANOVA with Bonferroni correction and Spearman correlation for association testing.

Ethical considerations

This research received ethical approval from the Manchester Institute of Clinical Sciences Research Ethics Committee (Protocol MICS-2022-RH-018, approved May 2022). All participants provided written informed consent. The research was conducted in accordance with the Declaration of Helsinki and UK Health Research Authority requirements. Patient data were handled in compliance with the UK Data Protection Act 2018 [10].

Results

Serum uric acid levels differed significantly across all five groups ($p < 0.001$). Table 1 presents the complete metabolic and inflammatory profiles.

Table 1: Metabolic and inflammatory parameters across five clinical groups

Parameter	Controls	Asymp. HU	Acute	Intercrit.	Chronic
SUA (mg/dL)	5.1 ± 0.9	7.8 ± 1.1	9.4 ± 1.3	8.1 ± 1.2	10.2 ± 1.4
XO Activity (mU/mL)	8.3 ± 2.4	14.7 ± 3.8	19.2 ± 4.6	15.4 ± 3.9	21.8 ± 5.1
CRP (mg/L)	1.8 ± 0.7	3.4 ± 1.2	24.7 ± 11.3	5.7 ± 2.3	8.9 ± 3.7
IL-1 β (pg/mL)	1.2 ± 0.4	2.1 ± 0.8	18.4 ± 7.6	3.8 ± 1.4	6.3 ± 2.8
24h uric acid (mg)	487 ± 124	673 ± 187	842 ± 214	718 ± 198	594 ± 167

SUA: serum uric acid; XO: xanthine oxidase; CRP: C-reactive protein; IL-1 β : interleukin-1 beta. HU: hyperuricemia; Asymp: asymptomatic; Intercrit: intercritical. Values are mean $\pm$ SD. All parameters significantly different across groups ($p < 0.001$)




Fig 1: Box plot distribution of serum uric acid levels across five clinical groups. The dashed red line indicates the monosodium urate supersaturation threshold (6.8 mg/dL). Boxes represent interquartile range; horizontal lines indicate medians

Table 2: Correlation matrix between metabolic parameters and disease severity score

Variable Pair	r	p-value	95% CI
SUA vs. Severity	0.74	<0.001	0.67-0.80
XO vs. SUA	0.68	<0.001	0.59-0.75
CRP vs. Severity	0.71	<0.001	0.63-0.78
IL-1 β vs. SUA	0.58	<0.001	0.47-0.67
24h excretion vs. SUA	0.43	<0.001	0.31-0.54

r: Spearman correlation coefficient; CI: confidence interval. Severity scored on composite clinical scale (0-10)




Fig 2: Violin plot showing the distribution of C-reactive protein concentrations across clinical groups. Plot width reflects data density; red lines indicate means; white lines indicate medians. Note the markedly elevated and broadly distributed CRP values during acute gout flares.

Comprehensive interpretation

Xanthine oxidase activity emerged as a strong independent correlate of serum uric acid concentration ($r = 0.68$), supporting its role as a rate-limiting determinant of urate production. Notably, chronic tophaceous gout patients showed the highest XO activity (21.8 ± 5.1 mU/mL) despite relatively lower 24-hour urinary uric acid excretion (594 ± 167 mg/day), suggesting combined overproduction

and underexcretion in advanced disease. The inflammatory profile revealed that even intercritical patients and chronic tophaceous patients without active flares maintained elevated CRP and IL-1 β levels above control values, indicating persistent subclinical inflammation. Figure 3 illustrates the purine degradation pathway leading to uric acid formation and crystal deposition.




Fig 3: Schematic of the purine degradation pathway showing the catabolic routes from adenine and guanine nucleotides through hypoxanthine and xanthine to uric acid, catalyzed by xanthine oxidase (XO). When serum urate exceeds the supersaturation threshold, monosodium urate (MSU) crystals deposit in joints. ADA: adenosine deaminase; PNP: purine nucleoside phosphorylase.

Discussion: The progressive elevation of xanthine oxidase activity across gout stages observed here provides metabolic evidence supporting the current treatment paradigm favoring XO inhibitors as first-line urate-lowering therapy [11]. Allopurinol and febuxostat target this enzyme directly, and their clinical efficacy correlates with the magnitude of XO activity reduction achieved. Our finding that XO activity explains approximately 46% of the variance in serum uric acid levels ($r^2 = 0.46$) suggests that while XO-mediated overproduction is a major contributor, renal underexcretion and other factors account for a substantial portion of hyperuricemia.

The persistent inflammatory state in intercritical and chronic tophaceous patients warrants particular attention. Traditional teaching held that gout flares represent discrete inflammatory events separated by asymptomatic intervals. Our data, showing elevated CRP (5.7 and 8.9 mg/L respectively) and IL-1 β (3.8 and 6.3 pg/mL) well above control values, align with emerging evidence that urate crystal deposits continuously activate the innate immune system even between clinically apparent flares [12]. This subclinical inflammation likely contributes to the increased cardiovascular risk observed in gout patients.

The reduction in 24-hour urinary uric acid excretion observed in the chronic tophaceous group, despite having the highest serum levels, is consistent with progressive renal urate handling impairment in advanced gout. This creates a vicious cycle: higher serum urate leads to greater crystal burden, which may further compromise renal function through urate nephropathy, in turn reducing excretory capacity [13]. Breaking this cycle through early initiation of urate-lowering therapy, ideally during the asymptomatic hyperuricemia phase, could prevent the escalating tissue damage that characterizes disease progression.

Limitations

This research is limited by its cross-sectional design, which captures associations but cannot establish temporal causation. The sample sizes in the non-AD dementia and chronic tophaceous groups were modest, potentially limiting statistical power for subgroup analyses. Plasma XO activity may not fully reflect tissue-level enzyme expression, particularly in the joint synovium where local production may differ from circulating levels. Additionally, dietary purine intake was not controlled, introducing a potential confounding variable [14].

Conclusions

This research established quantitative relationships between purine catabolic enzyme activity, serum urate concentrations, and inflammatory profiles across the full clinical spectrum of gout. Xanthine oxidase activity showed strong positive correlation with serum uric acid levels and progressively increased from healthy controls through chronic tophaceous disease. The identification of persistent subclinical inflammation in intercritical and chronic tophaceous patients reinforces the concept that gout is not simply a disease of intermittent acute flares but rather a chronic inflammatory condition with systemic consequences. The combined metabolic and inflammatory phenotyping approach employed here may help identify individuals with asymptomatic hyperuricemia at highest risk of progressing to clinical gout, potentially guiding decisions regarding early pharmacological intervention. Future longitudinal investigations should track these parameters over time to determine whether baseline xanthine oxidase activity and inflammatory markers can predict individual progression trajectories and response to urate-lowering therapy.

Acknowledgements

Funding sources

This research was supported by the UK National Institute for Health Research through the Clinical Research Network.

Institutional support

The authors acknowledge Manchester Institute of Clinical Sciences for providing access to the immunoassay laboratory and rheumatology outpatient facilities.

Contributions not qualifying for authorship

We thank Dr. Catherine Mills for polarized light microscopy and crystal identification, and Ms. Helen Bradshaw for coordinating patient recruitment.

References

1. Dalbeth N, Merriman TR, Stamp LK. Gout. *Lancet*. 2016;388(10055):2039-2052.
2. Kratzer JT, Lanasma MA, Murphy MN, Cicerchi C, Graves CL, Tipton PA, *et al*. Evolutionary history and metabolic insights of ancient mammalian uricases. *Proc Natl Acad Sci USA*. 2014;111(10):3763-3768.
3. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. *J Physiol*. 2004;555(Pt 3):589-606.
4. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. *Nat Rev Rheumatol*. 2015;11(11):649-662.
5. Pascual E, Addadi L, Andrés M, Sivera F. Mechanisms of crystal formation in gout: a structural approach. *Nat Rev Rheumatol*. 2015;11(12):725-730.
6. Richette P, Bardin T. Gout. *Lancet*. 2010;375(9711):318-328.
7. Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, *et al*. 2015 gout classification criteria. *Ann Rheum Dis*. 2015;74(10):1789-1798.
8. Beckman JS, Parks DA, Pearson JD, Marshall PA, Freeman BA. A sensitive fluorometric assay for measuring xanthine dehydrogenase and oxidase in tissues. *Free Radic Biol Med*. 1989;6(6):607-615.
9. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature*. 2006;440(7081):237-241.
10. United Kingdom. Data Protection Act 2018. London: The Stationery Office; 2018. Chapter 12.
11. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, *et al*. 2020 American College of Rheumatology guideline for management of gout. *Arthritis Care Res*. 2020;72(6):744-760.
12. Dalbeth N, Pool B, Gamble GD, Smith T, Callon KE, McQueen FM, *et al*. Cellular characterization of the gouty tophus. *Arthritis Rheum*. 2010;62(5):1549-1556.
13. Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010. *Semin Arthritis Rheum*. 2013;42(6):551-561.
14. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. *N Engl J Med*. 2004;350(11):1093-1103.
15. Stamp LK, Chapman PT. Urate-lowering therapy: current options and future prospects for elderly patients with gout. *Drugs Aging*. 2014;31(11):777-786.